China-based drugmaker Simcere Zaiming has granted NextCure the rights to develop and commercialize its experimental cancer therapy SIM0505 worldwide, excluding the Greater China region. Under the agreement, Simcere stands to receive up to US$745 million in upfront and milestone payments, in addition to tiered royalties on future sales.

 
Editor: Lan Suying